Link to paper Venema CM, Bense RD, Steenbruggen TG, Nienhuis HH, Qiu SQ, van Kruchten M, Brown M, Tamimi RM, Hospers GAP, Schröder CP, Fehrmann RSN, de Vries EGE. Abstract The androgen receptor (AR) is a drug target in breast cancer, and AR-targeted therapies have induced tumor responses in breast cancer patients. In this review,…
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5545-0 Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt- Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann…
https://onlinelibrary.wiley.com/doi/abs/10.1002/path.5280 Stutvoet TS, Kol A, de Vries EGE, de Bruyn M, Fehrmann RSN, Terwisscha van Scheltinga AGT, de Jong S. Abstract Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with non‐small cell lung cancer (NSCLC). Still, many patients do not respond to…
http://clincancerres.aacrjournals.org/content/early/2019/02/09/1078-0432.CCR-18-2918.long Moek KL, Waaijer SJH, Kok IC, Suurs FV, Brouwers AH, Menke-van der Houven van Oordt CW, Wind TT, Gietema JA, Schröder CP, Mahesh SVK, Jorritsma-Smit A, Lub-de Hooge MN, Fehrmann RSN, de Groot DJ, de Vries EG. ABSTRACTPurpose: Biodistribution of bispecific antibodies in patients is largely unknown. We therefore performed a feasibility study in nine…
https://www.nature.com/articles/s41467-018-08013-z He Y, Bouwstra R, Wierssma VR, de Jong M, Jan Lourens H, Fehrmann RSN, de Bruyn M, Ammatuna E, Huls G, van Meerten T, Bremer E ABSTRACTCD47 is a prominent new target in cancer immunotherapy, with antagonistic antibodies currently being evaluated in clinical trials. For effective evaluation of this strategy it is crucial to…
https://www.nature.com/articles/s41467-018-07927-y Heijink AM, Talens F, Jae LT, van Gijn SE, Fehrmann RSN, Brummelkamp TR, van Vugt MATM ABSTRACTLoss of BRCA2 affects genome stability and is deleterious for cellular survival. Using a genome-wide genetic screen in near-haploid KBM-7 cells, we show that tumor necrosis factor-alpha (TNFα) signaling is a determinant of cell survival upon BRCA2 inactivation.…
https://www.tandfonline.com/doi/full/10.1080/2162402X.2018.1558664 Thijs T. Wind, Mathilde Jalving, Jacco J. de Haan, Elisabeth G. E. de Vries, Marcel A. T. M. van Vugt, Dirk-Jan Reijngoud, Rozemarijn S. van Rijn, John B. A. G. Haanen, Christian U. Blank, Geke A. P. Hospers & Rudolf S. N. Fehrmann AbstractThis study aimed to establish the number of expression-based molecular subclasses…
Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. https://www.nature.com/articles/s41388-018-0522-7 de Boer HR, Pool M, Joosten E, Everts M, Samplonius DF, Helfrich W, Groen HJM, van Cooten S, Fusetti F, Fehrmann RSN, de Vries EGE, van Vugt MATM Abstract Tumor responses to cancer therapeutics are generally monitored every 2-3 months based on…
TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells. https://www.nature.com/articles/s41388-018-0470-2 van Gijn SE, Wierenga E, van den Tempel N, Kok YP, Heijink AM, Spierings DCJ, Foijer F, van Vugt MATM, Fehrmann RSN Abstract Genomic instability is a hallmark feature of cancer cells, and can be caused by defective DNA repair,…
Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. https://www.cancertreatmentreviews.com/article/S0305-7372(18)30134-8/fulltext Rico D. Bense, Si-Qi Qiu, Elisabeth G.E. de Vries, Carolien P. Schröder, Rudolf S.N. Fehrmann Abstract Extended endocrine therapy can reduce recurrences occurring more than 5 years after diagnosis (late recurrences) in estrogen receptor (ER)-positive breast cancer. Given…